34 results about "Dysbacterioses" patented technology

Provided herein are methods for modulating the intestinal microbial profile and for reducing intestinal dysbiosis in type 2 diabetic or pre-diabetic subjects, comprising administering metformin or a derivative or salt thereof and one or more probiotic microorganisms selected from Lactobacillus plantarum, Lactobacillus bulgaricus, Lactobacillus gasseri, Bifidobacterum breve, Bifidobacterium animalis subsp. lactis, Bifidobacterium bifidum, Streptococcus thermophilus and Saccharomyces boulardii. Also provided are methods for treating type 2 diabetes or an associated metabolic complication or condition and for delaying the onset of type 2 diabetes in pre-diabetic subjects, comprising administering one or more probiotic microorganisms selected from Lactobacillus plantarum, Lactobacillus bulgaricus, Lactobacillus gasseri, Bifidobacterum breve, Bifidobacterium animalis sub sp. lactis, Bifidobacterium bifidum, Streptococcus thermophilus and Saccharomyces boulardii.

Provided herein are methods for decreasing dysbiosis, restoring the microbiome, and / or increasing recovery of a healthy microbiome ( e.g. following a dysbiosis inducing event), by administering pharmaceutical compositions to a subject. Also provided are methods for protecting the microbiome of a subject and / or colonizing the microbiome of a subject by administering pharmaceutical compositions to the subject.

The present invention provides methods for determining if a patient is likely to benefit from a cancer treatment, by determining if said patient has a gut dysbiosis with an over representation of certain bacterial species. The present invention also provides probiotic strains to improve the efficacy of a cancer treatment, especially chemotherapy, in patients in need thereof.

The present invention provides methods for determining if a patient is likely to benefit from a cancer treatment, by determining if said patient has a gut dysbiosis with an over representation of certain bacterial species. The present invention also provides probiotic strains to improve the efficacy of a cancer treatment, especially chemotherapy, in patients in need thereof.

The invention provides a prebiotic-containing pharmaceutical composition for regulating micro-ecological balance of the female vagina, preparation and use. The prebiotic-containing pharmaceutical composition consists of repair bacteriostatic solution a, maintenance bacteriostatic solution b and a bacteriostatic spray c, and the repair bacteriostatic solution a, the maintenance bacteriostatic solution b and the bacteriostatic spray c are combined for use. According to the invention, by researching and developing the bacteriostatic solution containing prebiotics for regulating microecological balance of the female vagina, the microecological normal environment of the vagina is inhibited and repaired, and the prebiotic-containing pharmaceutical composition solves the problem that a conventional gynecological lotion kills the prebiotics while killing pathogenic bacteria so as to cause vaginal dysbacteriosis and low immunity, resulting in repeated attack of vaginitis.

The invention relates to an application of a composition lotion in preparation of a medicine for treating male balanitis. The formula is reasonable and simple, use is convenient, the growth and reproduction environment of bacteria and fungi is changed, and the purpose of broad-spectrum sterilization is achieved. The 2-5% sodium bicarbonate external washing liquid is used for soaking and externally washing the glans penis prepuce, the acid environment of the glans penis prepuce cavity is changed, the acid small environment for bacteria and fungi to survive is lost, the broad-spectrum antibacterial purpose is achieved, and the related external soaking and external washing liquid is free of coloring, irritation and dead angles and can be distributed in all directions. And antibiotic drug resistance and dysbacteriosis side effects are avoided.

The invention relates to microbiology and medicine and can be used to prevent and treat diseases and conditions associated with disruption of normal (autochthonous) microflora (microbiota) in humans or animals. In particular, a solution for recovery or creation of the subject's microflora comprising an active component containing microorganisms isolated from the microflora of the subject or the donor, wherein the active component can be enriched with bacteriophages of said microflora and / or additional microorganisms of the microflora cultivated on a nutrient medium, while the additional microorganisms of the microflora include microorganisms of the microflora that are yet nonculturable in the absence of the host organism, is proposed. Also provided are a pharmaceutical dosage form comprising the above solution and methods for prevention or treatment of diseases and / or conditions associated with and / or accompanied by a disorder or lack of the subject's own microflora, comprising administering the solution or pharmaceutical dosage form.

The present invention provides a method for determining the likelihood of a gastrointestinal dysbiosis in an individual, the method comprising providing a test data set, wherein the test data set comprises at least one microbiota profile, the microbiota profile being a distribution of relative levels of a plurality of microorganisms or groups of microorganisms in a sample from the gastrointestinal tract of said individual and wherein each level of each microorganism or group of microorganisms is a distribution element of said test data set, to said The test data set applies at least one loading vector determined from a latent variable within a horizontal distribution of the plurality of microorganisms or groups of microorganisms in corresponding gastrointestinal samples from a plurality of normal individuals, thereby generating a first projection data set, to applying a transposed version of the at least one loading vector to the first projection data set, thereby producing a second projection data set, comparing the test data set with the second projection data set and combining the second projection data set and the difference between the corresponding distribution elements of the test data set, and combining the difference with the plurality of microorganisms or microorganisms in the corresponding gastrointestinal samples from a plurality of normal individuals and / or individuals with dysbiosis comparing the normal to dysbiotic threshold values ​​determined by the correspondence analysis of the cohorts, applying at least one eigenvalue to said first projection data set, said eigenvalues ​​being determined by said at least one loading vector, and combining each The resulting values ​​of a distribution element and combining the combined value with the flora normal to Dysbiotic thresholds are compared, wherein a microbiota profile having said combined difference or said combined result above said respective normobacterial to dysbiotic thresholds is indicative of the likelihood of dysbiosis.

This document relates to biomarkers of gut microbiota dysbiosis. Bacteria that are increased or decreased in gut microbiota dysbiosis can be used as biomarkers to predict dysbiosis in patients with diarrhea and / or to predict susceptibility to Clostridium difficile infection (CDI). In addition, provided herein are compositions including at least three bacteria that are decreased in gut microbiota dysbiosis which can be used, for example, to restore heathy gut microbiota (e.g., by probiotic or by fecal microbiota transplant) to treat CDI.

A use of isomaltulose in preparing a vaginal composition, wherein the amount of isomaltulose is 0.05-20w / w%. A composition for the vagina, which contains 0.05-20w / w% isomaltulose, and the composition can be a combination of health products, health care products, cleaning products, care products, deodorants, cosmetics, and disinfectants a method of non-therapeutic vaginal health care by administering said composition to a woman's vagina, and a method of non-therapeutic vaginal hygiene, and a method of enhancing vaginal acidity, and a method of promoting intravaginal A method for the growth of lactobacilli, and a method for the prevention and treatment of vaginal flora disorders, in particular bacterial vaginosis.

The present invention provides therapeutic compositions comprising microbial populations for the prevention, treatment and alleviation of symptoms associated with dysbiosis in mammalian subjects, such as humans.

The invention relates to a method for establishing a grass carp intestinal flora imbalance model. The method for establishing the grass carp intestinal flora imbalance model is characterized in that grass carp is used as an experimental animal and is fed with mixed antibiotics for 28 days, and the antibiotics are prepared from 2g / kg of florfenicol, 2g / kg of enrofloxacin, 2g / kg of metronidazole and 1g / kg of vancomycin. The method for establishing the grass carp intestinal flora imbalance model has the advantages that an effective tool is provided for researching the pathogenesis of bacterial enteritis and screening effective medicines and beneficial microorganisms for treating enteritis.

The invention provides a new tertiary amine compound, which can reduce the pH value of the environment under the action of acid-producing bacteria, exert an antibacterial effect, and has pH-sensitive characteristics, which solves the problem of bacterial flora imbalance caused by the lack of selectivity of traditional antibacterial agents question.